Laura A. Cisar

Prognostic Role of <i>KRAS</i> and <i>BRAF</i> in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

Arnaud Roth, Sabine Tejpar, Mauro Delorenzi et al. · Journal of Clinical Oncology · 2009 · 1.1K citations · Full text

Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate

Caio M. Rocha Lima, Mark R. Green, Robert Rotche et al. · Journal of Clinical Oncology · 2004 · 580 citations · Full text

Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3

Eric Van Cutsem, Roberto Labianca, G. Bodoky et al. · Journal of Clinical Oncology · 2009 · 466 citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +13

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

Magdolna Dank, J. Załuski, Carlo Barone et al. · Annals of Oncology · 2008 · 342 citations · Full text

Oncology, Esophageal Cancer, Gastrointestinal Oncology +9

Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer

A. Roth, Mauro Delorenzi, Sabine Tejpar et al. · JNCI Journal of the National Cancer Institute · 2012 · 276 citations · Full text